CORCEPT THERAPEUTICS INC
Tremor tracks 7 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 3 insiders sold shares within a monthSince Aug 26, 2026+4.4
Trials
- CORTCorcept Therapeutics4Calm
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Running, no new patientsPhase 2125 patientsMain results: Dec 2026 - CORTCorcept Therapeutics4Calm
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Running, no new patientsPhase 3381 patientsMain results: Mar 31, 2025 - CORTCorcept Therapeutics4Calm
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Signing up patientsPhase 280 patientsMain results: Sep 2027 - CORTCorcept Therapeutics4Calm
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Signing up patientsPhase 1/250 patientsMain results: Sep 2026 - CORTCorcept Therapeutics4Calm
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Signing up patientsPhase 2270 patientsMain results: Aug 2026 - CORTCorcept Therapeutics4Calm
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
FinishedPhase 3137 patientsMain results: Sep 19, 2024 - CORTCorcept Therapeutics4Calm
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
FinishedPhase 3152 patientsMain results: Apr 8, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
92 sales (5 not pre-planned) · 0 purchases
- Maduck SeanLarge shareholder · Nov 3, 2026Sold 8,617 sharesabout $707 thousand · pre-planned
- Maduck SeanLarge shareholder · Nov 3, 2026Sold 4,542 sharesabout $376 thousand · pre-planned
- Maduck SeanLarge shareholder · Nov 2, 2026Sold 11,841 sharesabout $964 thousand · pre-planned
- Vieira Roberto WandenkolkPresident, Oncology · Nov 2, 2026Sold 6,657 sharesabout $537 thousand · pre-planned
- Vieira Roberto WandenkolkPresident, Oncology · Nov 2, 2026Sold 1,676 sharesabout $137 thousand · pre-planned
- WILSON JAMES NBoard member · Oct 15, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 3, 2026
- Shared quarterly results; Shared information with investorsNews report (8-K)Nov 3, 2026
- An executive or board member joined or left; Shared information with investorsNews report (8-K)Sep 23, 2026
- Quarterly reportQuarterly report (10-Q)Jul 29, 2026
- Shared quarterly results; Shared information with investorsNews report (8-K)Jul 29, 2026